UBS Group
BLCM

UBS Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

UBS Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,057
Closed -$1.01K – 10305
2023
Q1 		$1.01K Sell
3,057
-453
-13% -$418 ﹤0.01% 8853
2022
Q4 		$2.53K Buy
+3,510
New +$3.48K ﹤0.01% 9664
2022
Q3 		– Sell
-2,422
Closed -$3K – 11400
2022
Q2 		$3K Sell
2,422
-249
-9% -$376 ﹤0.01% 9445
2022
Q1 		$6K Sell
2,671
-4,303
-62% -$7K ﹤0.01% 9041
2021
Q4 		$10K Buy
6,974
+5,502
+374% +$11.1K ﹤0.01% 8837
2021
Q3 		$4K Sell
1,472
-4,437
-75% -$13.5K ﹤0.01% 8731
2021
Q2 		$20K Sell
5,909
-98
-2% -$314 ﹤0.01% 7362
2021
Q1 		$23K Sell
6,007
-3,202
-35% -$13.9K ﹤0.01% 7257
2020
Q4 		$32K Buy
9,209
+1,181
+15% +$4.99K ﹤0.01% 6585
2020
Q3 		$53K Sell
8,028
-2,341
-23% -$15.9K ﹤0.01% 5611
2020
Q2 		$77K Buy
10,369
+2,094
+25% +$14.3K ﹤0.01% 5519
2020
Q1 		$39K Buy
8,275
+3,933
+91% +$42.2K ﹤0.01% 6023
2019
Q4 		$56K Buy
4,342
+690
+19% +$6.37K ﹤0.01% 6290
2019
Q3 		$38K Buy
3,652
+1,814
+99% +$23.7K ﹤0.01% 6357
2019
Q2 		$31K Sell
1,838
-382
-17% -$10.3K ﹤0.01% 6317
2019
Q1 		$74K Sell
2,220
-2,146
-49% -$71.7K ﹤0.01% 5289
2018
Q4 		$128K Buy
4,366
+2,487
+132% +$110K ﹤0.01% 5327
2018
Q3 		$115K Buy
1,879
+206
+12% +$13.9K ﹤0.01% 5482
2018
Q2 		$124K Buy
1,673
+1,171
+233% +$91.3K ﹤0.01% 5290
2018
Q1 		$33K Sell
502
-26
-5% -$1.96K ﹤0.01% 6023
2017
Q4 		$44K Sell
528
-1,009
-66% -$98.9K ﹤0.01% 5947
2017
Q3 		$178K Buy
1,537
+466
+44% +$49K ﹤0.01% 4925
2017
Q2 		$125K Buy
1,071
+931
+665% +$116K ﹤0.01% 5034
2017
Q1 		$17K Buy
140
+44
+46% +$5.76K ﹤0.01% 6279
2016
Q4 		$13K Sell
96
-244
-72% -$43.3K ﹤0.01% 6778
2016
Q3 		$68K Buy
340
+100
+42% +$17.2K ﹤0.01% 5264
2016
Q2 		$31K Buy
240
+170
+243% +$18.9K ﹤0.01% 5913
2016
Q1 		$7K Buy
70
+20
+40% +$2.18K ﹤0.01% 6874
2015
Q4 		$10K Sell
50
-149
-75% -$26.7K ﹤0.01% 7298
2015
Q3 		$29K Buy
199
+149
+298% +$27.3K ﹤0.01% 6335
2015
Q2 		$11K Sell
50
-69
-58% -$16.9K ﹤0.01% 7410
2015
Q1 		$28K Sell
119
-1,602
-93% -$388K ﹤0.01% 6626
2014
Q4 		$397K Buy
+1,721
New +$369K ﹤0.01% 4389

Other funds holding BLCM

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

UBS Group's BLCM Position: Q2 2023 in Review

UBS Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 3,057 shares — an estimated $1.01K sold.

UBS Group first reported a position in BLCM in Q4 2014 and held it in 33 quarters. The position peaked at $397K in Q4 2014. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

  • UBS Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 3,057 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.01K.
  • UBS Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 33 quarters.
  • UBS Group's Bellicum Pharmaceuticals, Inc. position peaked at $397K in Q4 2014.
  • 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.